GHJ’s Post

What happens when a healthcare tech company needs to navigate multiple offers and a complex merger? MedQIA, LLC approached GHJ for strategic guidance amid an evolving industry landscape. Our Growth Planning and Strategic Advisory Practice evaluated their options, advised on investment banking selection and supported them through the merger process with WorldCare Clinical. The outcome? The creation of Voiant, an industry-leading AI-based clinical trial imaging platform. Learn how GHJ’s strategic approach can help achieve successful outcomes for your business. https://bit.ly/4dq5T2G #YourHomeTeamAdvantage

This merger marks a significant milestone in the advancement of biotech and healthcare innovation. Aquiva Medical Inc., powered by its groundbreaking technologies and strategic partnerships, is poised to make a lasting impact on the industry. For further information and updates, please visit the official channels of BHPA Inc. and Aquiva Medical Inc. #BHPAInc #AquivaMedical #Biotech #Innovation #Healthcare #TransdermalPatches #HydrogelTechnology #MergerAnnouncement

MedTech M&A Heating Up in 2024: Who's Next? Analysts predicted a surge, and we're starting to see it. Boston Scientific's Axonics, Inc. deal leads the pack, but Johnson & Johnson and Baxter International Inc. are also making moves this year. My Questions: Will the FTC play spoiler, or is the regulatory climate shifting for big medtech mergers? With these deals, does staying competitive mean going BIG or finding your niche? What under-the-radar companies are ripe for acquisition? Your Take? Share below in the comments! #MedTech #Acquisitions #HealthcareInnovation #MergersandAcquisitions #Baxter #Medtronic #Johnsonandjohnson

Mergers and acquisitions have become integral drivers of change in the medical device industry. These strategic moves send ripples through the industry, influencing everything from innovation to market dynamics. Explore the profound impact of M&A activities on the medical device sector in our latest blog here: https://lnkd.in/eFhHxdgd

Interest rates coming down globally and we will see more and more mergers and acquisitions in all regions. Especially in Life Sciences, where regulatory affairs and compliance is critical, the consequences are often overlooked. M&A transactions not only have financial and legals aspects to consider, but also regulatory and compliance aspects, license transfers, filings, registrations, and much more. We can help you with your M&A activities no matter if you are a medical device manufacturer, Digital Health Start Up or Private equity firm. We are here to help. Contact us and let´s discuss how we can support you to maximize the commercial benefits. #DueDiligence #VentureCapital #PrivateEquity #Transformation #MergersAcquisition #LifeSciences #Medtech #IVD #DigitalHealth #Growth

Lot's of talk about the outlook for Medtech M&A over the next 12 months. So the timing is perfect for a discussion about the good, the bad, and the sometimes ugly parts of M&A transactions. This session will serve as a case study on the acquisition of SIA by Integra LifeSciences, offering an inside look at the real-life experiences of those who were at the heart of this deal. The conversation will cover the full spectrum of M&A, from strategic considerations and the ideal characteristics of an acquisition target to the challenges of managing relationships and navigating the acquisition process. SIA (Acquired by Integra LifeSciences) Co-Founders Alexei Mlodinow and Todd Cruikshank, along with Lauren Lacagnino, Sr. Director of Strategy & Business Development at Integra LifeSciences, will discuss key moments that shaped the deal, share insights on timing and market influences, and offer lessons learned that are valuable for anyone involved in the M&A process. Join us at this Fireside Chat: "SIA Story: The Good, the Bad, and the Ugly of M&A" scheduled for September 18th at 7:00 pm at LSI Europe ‘24 in Sintra, Portugal.

In terms of value, private equity deal activity in the UK saw a significant surge, increasing by 3254% in Q4 2023 compared to the previous quarter's total of $32.8 million, and marking an 8792% rise compared to Q4 2022. Despite this, related deal volume remained stable in Q4 2023 compared to the previous quarter, but was 33% lower than in Q4 2022. Within the British medical devices industry, GlobalData's Deals Database reported 2 private equity deals announced in Q4 2023, totaling $1.1 billion in value. The largest disclosed deal in the industry was the $1.1 billion institutional buy-out (IBO) of Alliance Medical Group by iCON Infrastructure Partners VI. For a comprehensive examination of disruptive themes and private equity deal activity, please refer to GlobalData's Medical Devices Industry Mergers and Acquisitions Deals by Top Themes report. https://lnkd.in/eG3M-TfZ. #GlobalData #Deals #UK #Themes #M&A #MedicalDevice

Recent Mergers and Acquisitions - With M&As on a downswing, it’s only a matter of time before pent-up demand kicks in and we see a surge of new investments. A quick look at one of the top 3 M&A Deals (thus far in 2024) Johnson & Johnson acquisition of Shockwave Medical Date closed: May 31, 2024 Value: $13.1 billion Industry: Healthcare In the largest healthcare deal of the year so far, Johnson & Johnson paid out over $13 billion – made up of a mix of cash on hand and debt – to take over medical device manufacturer Shockwave Medical. This purchase will expand Johnson & Johnson’s portfolio of coronary artery disease (CAD) and peripheral artery disease (PAD) treatments, two fast growing segments of the healthcare market.

Research shows that a staggering 70% to 90% of acquisitions fail to achieve their intended outcomes. The main reason for this... ...ineffective integration. In the comments, you will find a whitepaper by Jitesh Tank highlighting that the true value of an M&A deal is unlocked not at the closing table but during the integration process, in the months and years that follow. If you are a medical device company looking to expand its market share, diversify its product offerings, or gain a competitive edge, with M&A, it’s worth a read. #mergersandacquisitions #projectmanagement #waddellgroup #medicaldeviceprojectmanagement

𝐌𝐞𝐝𝐓𝐞𝐜𝐡’𝐬 𝐌𝐞𝐠𝐚-𝐃𝐞𝐚𝐥𝐬 𝐨𝐯𝐞𝐫 𝐭𝐡𝐞 𝐲𝐞𝐚𝐫𝐬!   I previously wrote about the #revenue and revenue #growth of some of the top medical companies. But growth can in different ways. It can be #organic, driven by internal expansion and increased productivity, or inorganic, achieved through mergers and #acquisitions.   The following are some of the biggest mergers and acquisitions in the #MedTech industry: 1- Medtronic acquisition of #Covidien for $43B 2- Boston Scientific acquisition of #Guidant for $27B 3- Abbott's acquisition of St Jude Medical for $25B 4- BD acquisition of #Bard for $24B 5- Danaher Corporation's acquisition of GE’s biopharma (Cytiva) for $21B 6- Thermo Fisher Scientific acquisition of #PPD for $21B 7- Johnson & Johnson acquisition of #Synthes for $20B 8- Johnson & Johnson acquisition of #Abiomed for $17B 9- Siemens Healthineers acquisition of #Varian for $16B   Would be interesting to see what the next mega-deal will be in the coming years, and why.   𝐋𝐢𝐦𝐢𝐭𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬   I enjoyed making this graph, but there is not much learning in looking at blockbuster acquisitions. The key point is not what companies pay for an acquisition. The real question is whether those acquisitions paid off and ended up creating value beyond what was paid for them, or did they end up being a complete failure, and most importantly why? That’s where the learnings are.   For example, #Covidien and #Varian have proven to be great acquisitions for both Medtronic and Siemens. Today over 25% of Medtronic's revenue comes from its Medical Surgical division aka Covidien. Over 15% of Siemens's revenue also comes from its Varian division.   On the other hand, the acquisition of #Guidant for $27 billion ended up being extremely painful for Boston Scientific. Shortly after the acquisition, the company faced major lawsuits and massive recalls, leading to the write-off of most of the acquisition value in the following years. At that time, Fortune Magazine called the acquisition "The (second) worst deal ever", placing it right after the AOL/Time Warner merger. Philips’ acquisition of #Respironics for $5.1 billion is another example of an acquisition that did not deliver as expected. Like Boston Scientific, Philips faced major recalls in coming years, leading to the write-off of most of the acquisition’s value, which raises the question “What exactly went wrong?” I will write more about some of these M&A cases in my upcoming posts.   * Views and ideas are my own. The content that I provide here is public and intended to be educational only and is not financial advice. I have personal investments in several public and private tech and medtech companies, but always encourage the readers to do their research.